NanoViricides Inc/ US6300873022 /
5/21/2024 10:10:00 PM | Chg. +0.0650 | Volume | Bid1:33:39 AM | Ask1:33:39 AM | High | Low |
---|---|---|---|---|---|---|
2.1800USD | +3.07% | 224,069 Turnover: 436,927.1605 |
2.1700Bid Size: 1,000 | 2.2300Ask Size: 100 | 2.2300 | 2.0700 |
Newsfile Corp
9/27/2021
NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Updat...
GlobeNewswire
9/14/2021
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointments of John Rossi, Ph.D. and ...
GlobeNewswire
7/21/2020
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds NanoViricides (NNVC) Investors of Proprietary Inves...
GlobeNewswire
7/16/2020
NanoViricides, Inc. Investors Who Purchased NNVC Securities After January 2020 And Suffered Losses G...
Newsfile Corp
3/5/2020
NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter C...
GlobeNewswire
5/31/2019
Antiviral Therapeutics Markets, Technologies, & Competitive Landscape 2019 Featuring 194 Companies w...
GlobeNewswire
2/26/2019
Influenza A Virus H7N9 Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mecha...
GlobeNewswire
2/13/2019
Global Antiviral Therapeutics Technologies, Markets & Companies Report 2019: Vaccines, Pharmaceutica...
GlobeNewswire
8/21/2018
President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., of NanoViricides, Inc., Disc...
GlobeNewswire
5/10/2018
Antiviral Therapeutics Research Report 2018: Technologies, Markets and Companies 2017-2027 - Profile...